Mycobacterium vaccae Vaccine Prevents Tuberculosis in HIV Positive People with Prior BCG Vaccination

A large trial in Tanzania found that a multiple-dose vaccination series using Mycobacterium vaccae was safe and partially effective -- a 39% risk reduction -- in preventing tuberculosis (TB) in HIV positive adults who had received the minimally effective BCG vaccine as children, researchers reported in the January 28, 2010 advance online edition of AIDS.

Two-drug Combination Shows Effectiveness against Drug-resistant Tuberculosis in a Laboratory Study

Tuberculosis (TB) is an opportunistic infection in people with HIV. The Centers for Disease Control and Prevention (CDC) considers HIV-TB coinfection as an AIDS diagnosis, regardless of the stage of HIV infection. HIV-TB coinfected patients with resistance to currently available anti-TB drugs are difficult to treat successfully.

Re-emergence of Drug-resistant Tuberculosis in HIV Positive People Is Due to Re-infection, Not Treatment Failure

Over the past 2 years, researchers have reported a growing number of cases of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) in people with HIV/AIDS.